• Sortina Pharma secured Vinnova funding to evaluate its leading sortilin inhibitors in a preclinical glioblastoma model.
• Studies at Uppsala University will guide candidate selection for clinical development, testing the compounds alone or with standard glioblastoma treatment temozolomide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.